ALL
From the Journals
TBI beats chemoconditioning for ALL transplants in children
Total body irradiation plus etoposide remains the conditioning regimen of choice.
From the Journals
Allo-HSCT improves disease-free, but not overall survival in adults with ALL, compared with ped-inspired chemo
Conference Coverage
In high-risk first relapse ALL, blinatumomab seen superior to consolidation chemo
Conference Coverage
Well tolerated with promising responses in ALL/LL: Venetoclax plus navitoclax plus chemotherapy
Delayed count recovery remains a key safety concern.
Conference Coverage
Highly effective in Ph-negative B-cell ALL: Hyper-CVAD with sequential blinatumomab
Conference Coverage
COVID-19–related outcomes poor for patients with hematologic disease in ASH registry
From the Journals
‘Impressive’ outcomes sans chemo in poor-prognosis ALL
Conference Coverage
Immunotherapy for ALL: Roles emerge in R/R disease, MRD+ disease
“Another very exciting development is that these immunotherapies are now demonstrating efficacy and increased tolerability over chemotherapy in...
Conference Coverage
Are HMAS appropriate for posttransplant maintenance in acute leukemias?
Not yet, hematologist/oncologist tells colleagues at ALF meeting.
From the Journals
Study: Complications from childhood ALL and its treatment are common, but can be managed
From the Journals
Orthopedic problems in children can be the first indication of acute lymphoblastic leukemia